CymaBay Therapeutics (NASDAQ:CBAY) has been given a $18.00 price objective by analysts at Oppenheimer in a research note issued on Sunday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price points to a potential upside of 47.54% from the stock’s current price.

Several other analysts have also weighed in on the company. Cantor Fitzgerald set a $20.00 price objective on CymaBay Therapeutics and gave the company a “buy” rating in a report on Sunday. BidaskClub lowered CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. ValuEngine lowered CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Zacks Investment Research raised CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Tuesday, April 9th. Finally, Piper Jaffray Companies set a $30.00 price objective on CymaBay Therapeutics and gave the company a “buy” rating in a report on Friday, March 1st. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. CymaBay Therapeutics has a consensus rating of “Buy” and a consensus target price of $19.63.

Shares of CymaBay Therapeutics stock opened at $12.20 on Friday. The stock has a market capitalization of $743.38 million, a P/E ratio of -9.68 and a beta of 1.83. CymaBay Therapeutics has a fifty-two week low of $6.31 and a fifty-two week high of $15.00.

In other CymaBay Therapeutics news, Director Carl Goldfischer sold 11,675 shares of the business’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $9.02, for a total transaction of $105,308.50. Following the sale, the director now directly owns 2,335 shares of the company’s stock, valued at approximately $21,061.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.50% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of CymaBay Therapeutics by 16.3% during the 4th quarter. BlackRock Inc. now owns 5,161,581 shares of the biopharmaceutical company’s stock valued at $40,622,000 after acquiring an additional 722,753 shares in the last quarter. Eagle Asset Management Inc. grew its holdings in shares of CymaBay Therapeutics by 0.3% during the 4th quarter. Eagle Asset Management Inc. now owns 2,852,973 shares of the biopharmaceutical company’s stock valued at $22,452,000 after acquiring an additional 8,207 shares in the last quarter. Vanguard Group Inc grew its holdings in shares of CymaBay Therapeutics by 4.1% during the 3rd quarter. Vanguard Group Inc now owns 2,789,188 shares of the biopharmaceutical company’s stock valued at $30,903,000 after acquiring an additional 109,989 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of CymaBay Therapeutics by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,789,188 shares of the biopharmaceutical company’s stock valued at $30,903,000 after acquiring an additional 109,989 shares in the last quarter. Finally, Foresite Capital Management IV LLC grew its holdings in shares of CymaBay Therapeutics by 30.0% during the 4th quarter. Foresite Capital Management IV LLC now owns 2,631,258 shares of the biopharmaceutical company’s stock valued at $20,708,000 after acquiring an additional 607,889 shares in the last quarter. 98.00% of the stock is currently owned by institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: Leveraged Buyout (LBO)

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.